Medro Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 7/10
Best for: compounded or brand semaglutide/tirzepatide with transparent tiered pricing and no membership, all 50 states
Medro is a solid telehealth option with balanced features and pricing.
What the monthly price covers
Medication
Included
Provider visits
Not disclosed
Shipping
Included
Lab work
Not disclosed
Coaching
Not disclosed
No insurance needed · Vetted by our editors
Medro (Medro Health Technologies, Inc.) is a telehealth brand whose GLP-1 program offers compounded semaglutide and tirzepatide, plus brand-name GLP-1s when eligible, via a partner medical group and licensed pharmacy partners in all 50 states. You start with an online intake and a licensed provider decides if treatment fits. Pricing is tiered by commitment: semaglutide $149–$199/mo and tirzepatide $224–$299/mo, shown before checkout, with free shipping and no membership. Final price can vary by dose, pharmacy, and eligibility. LegitScript-certified.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Vetted alternatives to Medro
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Medro at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Starting price
- $199/mo (Month-to-month; drops to $179/mo (3-month), $159/mo (6-month), or $149/mo (12-month). Illustrative — final price shown before checkout, may vary by dose/pharmacy/eligibility.)
- What's included
- Medication · Shipping
- Availability
- All 50 states
- FDA status
- No FDA warning letter on record
How we scored Medro
Each dimension is scored algorithmically from Medro’s real pricing, drugs offered, verification status, and disclosed inclusions — using the same six-dimension framework we apply to every provider.
Value25%
6.4/10At $199/mo, Medro runs about 17% above the $170 median for GLP-1 providers.
Effectiveness25%
7.7/10Medro offers both semaglutide and tirzepatide — the two GLP-1 molecules with the strongest published weight-loss trial outcomes.
User Experience15%
6.8/10Online intake and platform experience; 8 platform features disclosed.
Trust & Safety15%
7.7/10Key details fully confirmed by our editors; no FDA warning letters on file (last checked 2026-07-20).
Accessibility10%
7.9/10Medro treats patients in all 50 states.
Support10%
5.5/10Medro provides standard clinician follow-up; no extended coaching or community program is disclosed.
Providers that don’t post pricing up front score lower on Value and carry a cost-transparency note in their review. Read the full methodology →
How we verified this Medro review
Last checked July 2026- Confirmed current pricing across 2 dose/plan tiers
- Confirmed availability in all 50 states
- Confirmed what the monthly price does and doesn't include
- Checked the FDA warning-letter database for enforcement actions
- Walked the public intake/checkout flow on the provider's site
Pricing, availability, and compliance facts come from the provider's own site and primary regulatory records — see the sources below. Editorial confidence in this data: high.
GLP-1 medications Medro offers
Tap any medication to read our plain-English guide — how it works, dosing, side effects, and what the trials found.
Pricing
Prices re-verified
Month-to-month; drops to $179/mo (3-month), $159/mo (6-month), or $149/mo (12-month). Illustrative — final price shown before checkout, may vary by dose/pharmacy/eligibility.
Month-to-month; drops to $269/mo (3-month), $239/mo (6-month), or $224/mo (12-month). Illustrative — final price shown before checkout. Brand-name GLP-1 options also available if eligible.
Ready to get started?
Plans and promotions change often — check Medro's current pricing and active discounts before you decide.
What we like
- Covers both compounded semaglutide and tirzepatide and can prescribe brand-name GLP-1s when clinically appropriate.
- LegitScript-certified (seal #50716646), available in all 50 states, with tiered pricing shown before checkout.
- No membership fee and free expedited shipping on all orders; online intake with no appointment required in many cases.
- Prices drop with longer commitments (semaglutide to $149/mo, tirzepatide to $224/mo on a 12-month plan).
Watch-outs
- Does not name its compounding pharmacy or its clinical partner medical group, so the fulfillment chain is not verifiable.
- Pricing is described as illustrative and may change by dose, pharmacy availability, and eligibility — final cost shows only at checkout.
- Very new brand (2026, trademark pending) spanning many verticals, with a short track record in GLP-1 care.
- Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.
Is Medro worth it? Our verdict
Medro positions itself around one thing: compounded or brand semaglutide/tirzepatide with transparent tiered pricing and no membership, all 50 states. It runs $199/month — a premium to the category, so the extras need to justify it. It treats patients in all 50 states, so access isn't a barrier.
On top of the prescription itself, Medro points to LegitScript Certified, Brand GLP-1 options, and Free expedited shipping.
How much Medro actually costs
- Compounded semaglutide — $199/month
- Compounded tirzepatide — $299/month
For context, the typical ongoing price across the GLP-1 providers we track is around $170/month, so Medro's standing rate sits at the premium end.
For a direct comparison, RNK Health runs semaglutide and tirzepatide from $197/month — worth pricing against Medro before you commit.
Medications: what Medro prescribes
Medro prescribes semaglutide (the active drug in Wegovy and Ozempic) and tirzepatide (the active drug in Zepbound and Mounjaro) — the two most-studied weight-loss molecules on the market today. The medication is compounded at a licensed pharmacy rather than sold as a brand pen, which is what keeps the price down. The trade-off is the one every compounded provider shares: compounded drugs aren't FDA-approved as finished products.
Who Medro is best for — and who should skip it
A good fit if you…
- live anywhere in the US and want guaranteed access.
Look elsewhere if you…
- want the lowest total cost over 6–12 months — a flat-rate provider like bmiMD will likely beat the ongoing price.
- specifically want an FDA-approved brand-name pen.
- need to bill insurance — like most of this market, it's cash-pay.
Trust, safety, and medical oversight
Medro treats patients in all 50 states. We found no FDA warning letters on file for the provider. As with any compounded program, the most important step you can take is confirming which licensed pharmacy fills your prescription and what's in the formulation — we explain how in our scoring methodology.
Bottom line
Medro costs more than the budget end of the market, so it makes the most sense if its specific extras matter to you. If they don't, you can likely get the same medication for less elsewhere. If you're comparison-shopping, Care Bare Rx is one of the closest alternatives we track — worth a look before deciding.
The Bottom Line
Medro is a solid telehealth option with balanced features and pricing.
Ready to start with Medro?
Starting at $199/month. See current pricing and start your free consultation.
Medro might not be your best fit if…
We rank editorially, so here’s where a different provider we track may serve you better.
- If you want brand-name Ozempic, Wegovy, Mounjaro or Zepbound, consider GobyMeds.
- If the lowest possible monthly price is your top priority, consider Sesame Care (from $59/mo).
- If you want built-in coaching and behavior-change support, consider ShedRx.
Frequently Asked Questions
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
The primary regulatory filings and peer-reviewed studies cited throughout this Medro review:
Sources & methodology — as of July 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See Medro's current pricing
Plans start at $199/month. Start your free consultation to check eligibility and today's price.